Effects of a stimulant-free dietary supplement on body weight and fat loss in obese adults: a six-week exploratory study
- PMID: 24944372
- PMCID: PMC4052995
- DOI: 10.1016/S0011-393X(03)00058-4
Effects of a stimulant-free dietary supplement on body weight and fat loss in obese adults: a six-week exploratory study
Abstract
Background: Obesity is a well-established risk factor for cardiovascular disease, diabetes, hyperlipidemia, hypertension, osteoarthritis, and stroke. Stimulants, such as ephedrine and caffeine and their herbal counterparts, have proved effective in facilitating body weight loss, but their use is controversial due to their undesired effects. Other nutraceuticals have shown moderate success in reducing body weight, whereas several other compounds have demonstrated little or no effect. Therefore, a tolerable and effective nutraceutical that can increase energy expenditure and/or decrease caloric intake is desirable for body weight reduction.
Objective: The primary purpose of this study was to assess the tolerability and effectiveness of a novel, stimulant-free, dietary supplement containing glucomannan, chitosan, fenugreek, Gymnema sylvestre, and vitamin C on body weight and fat loss and change in body composition in obese adults.
Methods: In this single-center, prospective, randomized, double-blind, placebo-controlled study conducted at the University of Guelph (Guelph, Ontario, Canada), obese adults (aged 20-50 years; body mass index [BMI], ≥30 kg/m(2)) were randomized to the treatment or placebo group. The treatment group received 6 capsules of a dietary supplement containing a proprietary blend of glucomannan, chitosan, fenugreek, G sylvestre, and vitamin C daily for 6 weeks, and the placebo group received 6 capsules of rice flour daily for 6 weeks. Body weight; percentage of body fat; absolute fat mass; lean body mass; BMI; upper abdominal, waist, and hip circumference; and anthropometric measurements were recorded at baseline and at study end. Patients completed daily dietary intake records on days 1 to 3 and days 40 to 42. They also completed weekly activity logs throughout the study.
Results: Twenty-four subjects (mean [SD] age, 37.0 [8.2] years [range, 21-48years]; mean [SD] BMI, 35.7 [6.2] kg/m(2) [range, 28.9-50.9 kg/m(2)]) were assigned to the treatment group (8 women, 4 men) or the placebo group (9 women,3 men). Two subjects (8.3%; 1 patient [8.3%] from each group) dropped out for personal reasons unrelated to the study. No significant changes in the consumption of total calories; the percentage of calories ingested as carbohydrates, fat, or protein; or activity levels were found in either group throughout the study. Compared with the placebo group, the treatment group lost significantly more body weight (-2.3 kg vs 0.0 kg; P<0.01), percentage of body fat (-1.1% vs 0.2%; P<0.05), and absolute fat mass (-2.0 kg vs 0.2 kg; P<0.001). The treatment group also experienced a significantly greater reduction in upper abdominal circumference (-4.5 cm vs -0.7 cm), waist circumference (-4.1 cm vs 0.1 cm), and hip circumference (-2.9 cm vs 0.6 cm) compared with the placebo group (P<0.05 for all). No significant changes in heart rate or blood pressure were found in either group. Both the treatment and the placebo were well tolerated.
Conclusion: Within the context of this study, the novel combination of glucomannan, chitosan, fenugreek, G sylvestre, and vitamin C results in significant body weight and fat loss in obese adults. Disclosure: Derek E. Woodgate, MSc, is president and owner of NxCare Inc., which produces the dietary supplement containing glucomannan, chitosan, fenugreek, Gymnema sylvestre, and vitamin C (trade name Calorie-Care™).
Keywords: body composition; chitosan; dietary supplement; glucomannan; weight loss.
Similar articles
-
Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.Diabetes Obes Metab. 2000 Apr;2(2):105-12. doi: 10.1046/j.1463-1326.2000.00071.x. Diabetes Obes Metab. 2000. PMID: 11220522 Clinical Trial.
-
A pilot study investigating the effect of Caralluma fimbriata extract on the risk factors of metabolic syndrome in overweight and obese subjects: a randomised controlled clinical trial.Complement Ther Med. 2013 Jun;21(3):180-9. doi: 10.1016/j.ctim.2013.01.004. Epub 2013 Feb 23. Complement Ther Med. 2013. PMID: 23642949 Clinical Trial.
-
The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults.Int J Obes Relat Metab Disord. 2004 Sep;28(9):1149-56. doi: 10.1038/sj.ijo.0802693. Int J Obes Relat Metab Disord. 2004. PMID: 15311218 Clinical Trial.
-
[Simple obesity in children. A study on the role of nutritional factors].Med Wieku Rozwoj. 2006 Jan-Mar;10(1):3-191. Med Wieku Rozwoj. 2006. PMID: 16733288 Review. Polish.
-
Offspring body size and metabolic profile - effects of lifestyle intervention in obese pregnant women.Dan Med J. 2014 Jul;61(7):B4893. Dan Med J. 2014. PMID: 25123127 Review.
Cited by
-
Regular Consumption of Lipigo® Promotes the Reduction of Body Weight and Improves the Rebound Effect of Obese People Undergo a Comprehensive Weight Loss Program.Nutrients. 2020 Jun 30;12(7):1960. doi: 10.3390/nu12071960. Nutrients. 2020. PMID: 32630079 Free PMC article. Clinical Trial.
-
A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss.Obesity (Silver Spring). 2021 Jul;29(7):1102-1113. doi: 10.1002/oby.23110. Obesity (Silver Spring). 2021. PMID: 34159755 Free PMC article.
-
Dietary supplements for obesity.J Prev Med Hyg. 2022 Oct 17;63(2 Suppl 3):E160-E168. doi: 10.15167/2421-4248/jpmh2022.63.2S3.2757. eCollection 2022 Jun. J Prev Med Hyg. 2022. PMID: 36479472 Free PMC article. Review.
-
Fenugreek and Its Effects on Muscle Performance: A Systematic Review.J Pers Med. 2023 Feb 27;13(3):427. doi: 10.3390/jpm13030427. J Pers Med. 2023. PMID: 36983608 Free PMC article. Review.
-
A Meta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure.Medicina (Kaunas). 2018 Dec 12;54(6):109. doi: 10.3390/medicina54060109. Medicina (Kaunas). 2018. PMID: 30545156 Free PMC article.
References
-
- National Task Force on the Prevention and Treatment of Obesity Overweight, obesity, and health risk. Arch Intern Med. 2000;160:898–904. - PubMed
-
- Must A, Spadano J, Coakley E. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–1529. - PubMed
-
- Allison D.B, Fontaine K.R, Manson J.E. Annual deaths attributable to obesity in the United States. JAMA. 1999;282:1530–1538. - PubMed
-
- Cummings S, Parham E.S, Strain G.W. Position of the American Dietetic Association: Weight management. J Am Diet Assoc. 2002;102:1145–1155. - PubMed
-
- Flegal K.M, Carroll M.D, Kuczmarski R.J, Johnson C.L. Overweight and obesity in the United States: Prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord. 1998;22:39–47. - PubMed
LinkOut - more resources
Full Text Sources